Navigation Links
Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations


Three new kits target specific mutations using molecular beacon technology

Xiuyuan Hu Beti Belachew Lingyu Chen Haoqiang Huang Jason Zhang
Stratagene

Because of their unique hairpin conformation, molecular beacons can distinguish human DNA specimens that differ by a few nucleotides or only a single nucleotide. We developed three single-tube assay kits, based on molecular beacon technology, to quickly detect three common human gene mutations: One is a three-base-pair deletion in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, and the other two are single nucleotide substitutions in the coagulation factor II (prothrombin) gene and the HFE gene. Each kit includes two allele-specific molecular beacons, three genotype-specific DNA controls, target-specific PCR primers, and an optimized PCR buffer. Test results show that these kits possess adequate target specificity and good assay throughput.

Recent advances in the human genome project and in other areas of genetic research have revealed the value of single nucleotide polymorphisms (SNPs) in medical research and clinical diagnostics. The demand is growing for high-throughput screening methodologies that are low in cost yet specific enough to distinguish nucleic acid sequences differing by a single nucleotide. Currently used mutation detection techniques are either labor intensive and/or expensive (e.g., DNA sequencing) or do not detect all mutations (e.g., allele specific amplification and single-strand confirmation assay). However, molecular beacon technology overcomes these limitations.1,2

Molecular beacons are single-stranded oligonucleotides that possess a stem-and-loop hairpin structure. The loop portion of the molecule is a probe sequence, which is complementary to a target sequence, and the stem is formed by short complementary sequences located at the opposite ends of the molecule. The molecule is labeled with a fluorophore at one end and a quencher at the other end. When the unhybridized probe is in solution, it adopts a hairpin structure that brings the fluorophore and quencher sufficiently close to each other to allow efficient quenching of the fluorophore. When the molecular beacon is bound to its complementary target, the fluorophore and quencher are far enough apart so that the fluorophore cannot be quenched, and the molecular beacon fluoresces (Figure 1). The hairpin shape of the probe causes mismatched probe/target hybrids to easily dissociate at a significantly lower temperature than perfectly matched hybrids.2

Fig.1

The thermal instability of mismatched hybrids increases the specificity of molecular beacons, enabling them to distinguish targets that differ by only a single nucleotide. When conjugated to different fluorophores, two allele-specific molecular beacons can simultaneously discriminate the three possible genotype representations (two homozygotes and a heterozygote) of two allelic variants in a single reaction tube (Figure 1).

Convenient Single-Tube Format

Each assay kit includes two allele-specific molecular beacons with an exact sequence match to each of the two target sequence variants, genotype DNA controls (wild type/mutant homozygotes and heterozygote), target-specific PCR primers, and an optimized PCR buffer. The wild-type allele-specific molecular beacon is labeled with the fluorophore tetrachloro 6-carboxyfluorescein (TET), and the mutant allele-specific molecular beacon is labeled with the fluorophore 6-carboxyfluorescein (FAM). DABCYL is used as the quencher on both molecular beacons.

Fig.2

The assay is performed in a single PCR tube that contains a DNA template, both allele-specific molecular beacons and other PCR reagents. We carried out the amplification in the ABI Prism 7700 sequence detector. The genotype of a DNA sample is determined by measuring the endpoint fluorescence value (endpoint analysis, Figure 2) and/or the threshold cycle (Ct) value (real-time analysis) of the sample. Monitoring PCR reactions in real time produces a fluorescent signal during each cycle. Molecular beacon fluorescence is reported during each annealing step when the molecular beacon is bound to its complementary target (Figure 3 and Figure 4).

Results are displayed as an amplification plot that reflects the change in fluorescence during cycling. The threshold cycle is the cycle at which the fluorescent signal is first detectable above background. For the three assays described in the article, a Ct value of 20 to 32 indicates the presence of a specific allele and a Ct value of 40 indicates the absence of a specific allele. The maximum Ct value is 40 as PCR proceeds to 40 cycles.

The Specific Kits

The CFTR (DF508) Mx4000 molecular beacon allelic discrimination kitff, is designed to rapidly detect/screen the most common mutation that causes cystic fibrosis (CF). This mutation, a three-base-pair deletion, within exon 10 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, accounts for approximately 70% of all mutant CF alleles.3,4 The Factor II (G20210A) Mx4000 molecular beacon allelic discrimination kitff, is used to detect a common genetic variant in the coagulation factor II (prothrombin) gene. The mutation, a G to A substitution at nucleotide position 20210, is associated with elevated plasma prothrombin levels and an increased risk of deep vein thrombosis.5,6 The mutation is also being evaluated clinically as a risk factor for cardiovascular disease.7

The HFE (C282Y) Mx4000 molecular beacon allelic discrimination kitff, is used to detect a G to A substitution at the nucleotide position 845 of the HFE gene.8 This mutation, which changes cysteine to tyrosine at amino acid codon 282, is found in homozygous form in more than 80% of Caucasian patients suffering from hereditary haemochromatosis. One of the most common human genetic diseases, it characterized by an iron overload that eventually results in tissue damage and death to the patient. The estimated frequencies of the disease varies from 1 in 200 to 1 in 400 in individuals of Northern European descent.9

Assay Validation

Fig.4

The assay specificity of the three kits was determined by real-time PCR analysis using the ABI Prism 7700 sequence detector. First, validated genotype-specific human genomic DNA was used as PCR template, and the expected results were obtained by molecular beacon analysis (assay details in kits manual). Examples of the results for CFTR (DF508) allelic discrimination are shown in Figure 2 and Figure 3. An example of the results for factor II (G20210A) allelic discrimination is shown in Figure 4. Second, 50 human genomic DNA, previously genotype-characterized by PCR/RFLP analysis for the factor II and the HFE mutations, were tested, and results of the molecular beacon analysis were in complete agreement with those from the PCR/RFLP analysis. Third, 154 genotype-unknown human genomic DNA samples were genotyped by molecular beacon analysis for the three mutations, and results were confirmed for selected samples by DNA sequencing.

Conclusions

Use Stratagenes single-tube allelic discrimination assays to realize several advantages over existing mutation detection techniques: The hairpin-shaped molecular beacon probes are more specific in distinguishing single base-pair mismatches than linear probes.2 Because the test is performed in a closed tube and no post-PCR manipulation of samples is required, the test saves time and effort and significantly reduces the risk of PCR product carry-over contamination. Being able to use two allele-specific molecular beacons in the same PCR solution enables three possible genotype representations (two homozygotes and a heterozygote) of two allelic variants in target DNA to be determined at the same time. It also definitively discriminates a true negative result from a false negative result due to PCR failure. Finally, the technology can be adapted for high-throughput assays. Currently, with the 96-well PCR plate, it takes about 4 hours to completely screen 96 DNA samples; further enhancement of the assay throughput can be achieved by using a higher density plate format (e.g., 384-well format).

Acknowledgments

The authors thank the following: Dr. P.N. Ray (Molecular Diagnostic Laboratory, the Hospital for Sick Children, Toronto, Canada) for providing the CF genotype-specific human genomic DNA; Dr. J.W. Longshore (Molecular Diagnostic Laboratory, Greenwood Genetic Center, Greenwood, SC) and Dr. V.M. Pratt (LabCorp, Research Triangle Park, NC) for providing the factor II genotype-specific human genomic DNA; Dr. J.W. Longshore (Molecular Diagnostic Laboratory, Greenwood Genetic Center, Greenwood, SC) and Dr. C. Mura (Laboratoire de Genetique Moleculaire, CHU-UBO, France) for providing the HFE genotype-specific human genomic DNA; and Dr. Cindy WalkerPeach, Martha Frantz, Jeff Strauss, Peter Pingerelli, Dwight Dubois, David Boe, Connie Hansen, Becky Mullinax, and Joe Sorge of Stratagene for discussions, suggestions, and reagents.

REFERENCES

  1. Tyagi, S. and Kramer, F.R. (1996) Nature Biotech. 14: 303-308.

  2. Tyagi, S., et al. (1998) Nature Biotech. 16: 49-53.

  3. Riordan, J.R. et al. (1989) Science 245: 1066-1072.

  4. Kerem, B.S. et al. (1989) Science 245: 1073-1080.

  5. Degen, S.J.F and Davie, E.W. (1987) Biochemistry 26: 6165-6177.

  6. Poort , S.R. et al.(1996) Blood 88: 698-703.

  7. Ferrer-Antrunes, C. (1998) Clin. Chem. Lab. Med. 36: 897-906.

  8. Feder, J.N. et al. (1996) Nat. Genet. 13: 399-409.

  9. Edwards, C.Q. et al. (1988) N. Engl. J. Med. 318: 1355-1362.


'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
2. Using Validated siRNAs in Functional Genomic Assays
3. Nuclease Protection Assays: The Basics
4. Selection of Standards for Bio-Plex Cytokine Assays, Rev A
5. Feasibility of Multiplexing Bio-Plex Total Target and Phosphoprotein Assays
6. The Gradient Feature: Use in Optimization of Allelic Discrimination Assays, Rev B
7. The iCycler iQ Detection System for TaqMan Assays, Rev B
8. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
9. Caspase-3 Activation - An Indicator of Apoptosis in Image-Based Assays
10. Amplification Efficiency of TaqMan Gene Expression Assays
11. Cell Proliferation Assays
Post Your Comments:
(Date:3/26/2015)... 26, 2015 PRC Clinical, a Silicon-Valley ... several management and executive appointments effective immediately. , Mike ... (CFO) and member of the Board of Directors. Daniel ... and Sue Dowden will assume the position of Senior ... Chief Operations Officer (COO), has been appointed to the ...
(Date:3/26/2015)... SAN DIEGO , March 26, 2015  BioNano ... the appointment of  Terry Salyer as chief commercial ... building highly effective, worldwide sales teams in life sciences. ... Irys ® System, a genome-mapping platform to assemble ... and investigate structural variations. To date, 32 institutions located ...
(Date:3/26/2015)... 2015 PAREXEL International Corporation (Nasdaq: ... research organization , announced today that the ... acquire all of the business assets of privately-owned ... of specialized pharmacovigilance services, based in Chandigarh, ... assessment, monitoring, and prevention of adverse effects ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of ... Affairs at Align Technology, on “ Conducting Postmarket Registries ... 2015 Global Conference and Exhibition on April 25th through ... During the poster presentation, Ale Gicqueau and Victor Chen ... Postmarket Registry, the requirements and resources to conduct the ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3
... GeneGo, Inc., the leading systems biology tools company, ... Northwest National Laboratory (PNNL) has become a certified ... institution-wide access to GeneGo,s MetaCore data analysis suite, training ... technology to address complex national challenges in fundamental science ...
... firm, announced today that the company grew the ... 50% in 2008. Revenues for the year ... provider added long-term contracts in clinical trial and ... evaluation and mitigation strategies. The company maintained ...
... SurgiQuest, Inc. is pleased to announce it has entered ... Inc. (Nasdaq: ISRG ) in which SurgiQuest ... for use with Intuitive,s laparoscopic surgical robot. SurgiQuest,s technology ... it allows the surgeon to operate with an unprecedented ...
Cached Biology Technology:Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence 2Sentrx Exits 2008 with Strong Growth 2Sentrx Exits 2008 with Strong Growth 3SurgiQuest Signs a Development and Supply Agreement with Intuitive Surgical for MIS Access Utilizing the AirSeal(TM) Technology 2
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... in detail the dynamics of the nanoworld (the world at ... for example, when we try to drive a polyelectrolyte (a ... a nanopore if knots cause the translocation process to jam? ... sequencing method to electrochemically analyze every single strand by driving ...
... MADISON For the first time, Wisconsin researchers have ... cell (iPSC) technology, turned them into a laboratory model ... David Gamm, director of the UW,s McPherson Eye Research ... having a patient-specific model of the eye disease, which ...
... study following 110,645 workers who helped clean up after ... former Soviet territory of Ukraine shows that the workers ... results may help scientists better define cancer risk associated ... procedures such as computed tomography scans and other sources. ...
Cached Biology News:Pull with caution 2Cells from skin create model of blinding eye disease 2Chernobyl cleanup workers had significantly increased risk of leukemia 2Chernobyl cleanup workers had significantly increased risk of leukemia 3
E2F-5...
DAP12 Market Segment: Protein Kinases...
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Naphthol Blue Black, CI 20470...
Biology Products: